p53 autoantibodies predict subsequent development of cancer

International Journal of Cancer

Volumn 114, Issue 1, 2005, Pages 157-160

  Li, Yongliang ^a   Karjalainen, Antti ^b   Koskinen, Heikki ^b   Hemminki, Kari ^c   Vainio, Harri ^b   Shnaidman, Michael ^a   Ying, Zhiliang ^a   Pukkala, Eero ^d   Brandt Rauf, Paul W ^a,e  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b FINNISH INSTITUTE OF OCCUPATIONAL HEALTH   (Finland)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d FINNISH CANCER REGISTRY   (Finland)

^e NONE   (United States)

Author keywords

Biomarker; Cancer risk; p53 mutation; Predictive value

Indexed keywords

AUTOANTIBODY; BIOLOGICAL MARKER; PROTEIN P53;

AGED; ARTICLE; CANCER; CANCER RISK; CARCINOGENESIS; CONTROLLED STUDY; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; PREDICTION; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TUMOR SUPPRESSOR GENE;

ASBESTOSIS; AUTOANTIBODIES; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; ODDS RATIO; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 13244259268     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20715     Document Type: Article

References (21)

1. Hofseth LJ, Hussain SP, Harris CC. p53: 25 years after its discovery. Trends Pharmacol Sci 2004;25:177-81.
2. Soussi T. The p53 tumor suppressor gene: from molecular biology to clinical investigation. Ann NY Acad Sci 2000;910:121-37.
3. Harris CC. p53 tumor suppressor gene: at the crossroads of molecular carcinogenesis, molecular epidemiology, and cancer risk assessment. Environ Health Perspect 1996;104:435-9.
4. Hill KA, Sommer SS. p53 as a mutagen test in breast cancer. Environ Mol Mutagen 2002;39:216-27.
5. Downing SR, Russell PJ, Jackson P. Alterations in p53 are common in early stage prostate cancer. Can J Urol 2003;10:1924-33.
6. Soussi T. p53 antibodies in the sera of patients with various types of cancer: a review. Cancer Res 2000;60:1777-88.
7. Schlichtholz B, Tredaniel J, Lubin R, Zalcman G, Hirsch A, Soussi T. Analyses of p53 antibodies in sera of patients with lung carcinoma define immunodominant regions in the p53 protein. Br J Cancer 1994;53:5872-6.
8. Lubin R, Zalcman G, Bouchet L, Tredaniel J, Legros Y, Cazals D, Hirsch A, Soussi T. Serum p53 antibodies as early markers of lung cancer. Nat Med 1995;1:701-2.
9. Trivers GE, Cawley HL, DeBenedetti VM, Hollstein M, Marion MJ, Bennett D, Hoover ML, Prives CC, Tamburro CC, Harris CC. Anti-p53 antibodies in sera of workers occupationally exposed to vinyl chloride. J Natl Cancer Inst 1995;87:1400-7.
10. Trivers GE, DeBenedetti VM, Cawley HL, Caron G, Harrington AM, Bennett WP, Jett JR, Colby TV, Tazelaar H, Pairolero P, Miller RD, Harris CC. Anti-p53 antibodies in sera from patients with chronic obstructive pulmonary disease can predate a diagnosis of cancer. Clin Cancer Res 1996;2:1767-75.
11. Oksa P, Pukkala E, Karjalainen A, Ojajarvi A, Huuskonen MS. Cancer incidence and mortality among Finnish asbestos sprayers and in asbestosis and silicosis patients. Am J Ind Med 1997;31:693-8.
12. Teppo L, Pukkala E, Lehtonen M. Data quality and quality control of a population-based cancer registry. Acta Oncol 1994;33:365-9.
13. Li Y, Brandt-Rauf PW, Carney WP, Tenney DY, Ford JG. Circulating anti-p53 antibodies in lung cancer and relationship to histology and smoking. Biomarkers 1999;4:381-90.
14. Li Y, Asherova M, Marion MJ, Brandt-Rauf PW. Mutant oncoprotein biomarkers in chemical carcinogenesis. In: Mendelsohn ML, Mohr LC, Peelers JP. Biomarkers-medical and workplace applications. Washington: Joseph Henry Press, 1998. 345-53.
15. Husgafvel-Pursiainen K, Kannio A, Oksa P, Suitiala T, Koskinen H, Hemminki K, Smith S, Rosenstock-Leibu R, Brandt-Rauf PW. Mutations, tissue accumulations, and serum levels of p53 in patients with occupational cancers from asbestos and silica exposure. Environ Mol Mutagen 1997;30:224-30.
16. Guinee DG, Travis WD, Trivers GE, DeBenedetti VM, Cawley H, Welsh JA, Bennett WP, Jett J, Colby TV, Tazelaar H, Abbondanza SL, Pairolero P, et al. Gender comparisons in human lung cancer: analysis of p53 mutations, anti-p53 serum antibodies and c-erbB-2 expression. Carcinogen 1995;16:993-1002.
17. Brandt-Rauf PW, Smith S, Hemminki K, Koskinen H, Vainio H, Niman H, Ford J. Serum oncoproteins and growth factors in asbestosis and silicosis patients. Int J Cancer 1992;50:881-5.
18. Partanen R, Hemminki K, Koskinen H, Luo JC, Carney WP, Brandt-Rauf PW. The detection of increased amounts of the extracellular domain of the epidermal growth factor receptor in serum during carcinogenesis in asbestosis patients. J Occup Med 1994;36:1324-8.
19. Chene P. Targeting p53 in cancer. Curr Med Chem Anti-Cancer Agents 2001;1:151-61.
20. Bykov VJ, Selivanova G, Wiman KG. Small molecules that reactivate p53. Eur J Cancer 2003;39:1828-34.
21. Rosal R, Brandt-Rauf PW, Pincus MR, Wang H, Mao Y, Li Y, Fine RL. The role of alpha-helical structure in p53 peptides as a determinant for their mechanism of cell death: necrosis versus apoptosis. Adv Drug Deliv Rev 2004;in press.